Ecuador has approved the use of Chinese vaccine company CanSino Biologics Inc's (HKG: 6185) COVID-19 vaccine, Reuters news agency reported on Wednesday.
The President of Ecuador, Guillermo Lasso, had announced the purchase of six million doses of the CanSino shot, with the aim of vaccinating nine million people in the first 100 days of his government.
The Ecuador government is also negotiating the purchase of 18 million doses of Russia's Sputnik V COVID-19 vaccine and is asking pharmaceutical companies to speed up the delivery of doses they had previously agreed to provide.
According to Ecuador's health ministry, so far the country has vaccinated over a million people.
Ecuador expects to receive another 814,000 COVID-19 vaccines this week as part of deals already negotiated with laboratories, Reuters added.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV